Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Clarendon House, 2 Church Street HAMILTON HM11 |
Tel: | N/A |
Website: | https://www.kiniksa.com |
IR: | See website |
Key People | ||
Sanjiv K Patel Chairman of the Board, Chief Executive Officer | Mark Ragosa Chief Financial Officer, Senior Vice President | Eben Tessari Chief Operating Officer, Senior Vice President |
Ross Moat Senior Vice President and Chief Commercial Officer | John F. Paolini Senior Vice President and Chief Medical Officer | Michael R. Megna Chief Accounting Officer, Group Vice President - Finance |
Business Overview |
N/A |
Financial Overview |
For the three months ended 31 March 2024, Kiniksa Pharmaceuticals Ltd revenues increased 65% to $79.9M. Net loss increased 44% to $17.7M. Revenues reflect Product revenue, net increase of 85% to $78.9M. Higher net loss reflects Collaboration expenses increase from $8.3M to $20.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.18 to -$0.25. |
Employees: | 297 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $301.77M as of Mar 31, 2024 |
EBITDA (TTM): | -$28.80M as of Mar 31, 2024 |
Net annual income (TTM): | $8.65M as of Mar 31, 2024 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 70,939,178 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |